| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1156661B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0156661 |
| P932 | PMC publication ID | 4892570 |
| P698 | PubMed publication ID | 27257824 |
| P50 | author | Dana-Adriana Botesteanu | Q59707146 |
| P2093 | author name string | Jung-Min Lee | |
| Doron Levy | |||
| P2860 | cites work | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 |
| Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations | Q24614865 | ||
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| Effect of Screening on Ovarian Cancer Mortality | Q26253810 | ||
| Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis | Q26822545 | ||
| Ovarian cancer screening--current status, future directions | Q27004471 | ||
| The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention" | Q27025315 | ||
| Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas | Q27852671 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas | Q28538327 | ||
| Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis | Q28649475 | ||
| Age-specific incidence of cancer: Phases, transitions, and biological implications | Q30484186 | ||
| Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. | Q30724410 | ||
| The preclinical natural history of serous ovarian cancer: defining the target for early detection | Q33487678 | ||
| Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis | Q34209092 | ||
| Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement | Q34298836 | ||
| Menstruation in girls and adolescents: using the menstrual cycle as a vital sign | Q34578504 | ||
| The distal fallopian tube: a new model for pelvic serous carcinogenesis. | Q34601152 | ||
| Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro | Q35914153 | ||
| Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report | Q36285968 | ||
| A branching process model of ovarian cancer | Q36339013 | ||
| Modelling aspects of cancer dynamics: a review | Q36502898 | ||
| Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature | Q36603837 | ||
| No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study | Q36610368 | ||
| A stochastic numerical model of breast cancer growth that simulates clinical data. | Q36627141 | ||
| Comparative lesion sequencing provides insights into tumor evolution | Q36670136 | ||
| Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction | Q36924865 | ||
| The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells | Q36972761 | ||
| Clinical implications of using molecular diagnostics for ovarian cancers | Q37332490 | ||
| Transvaginal ultrasonography in ovarian cancer screening: current perspectives | Q37414923 | ||
| Development of an ovarian cancer symptom index: possibilities for earlier detection. | Q39777813 | ||
| A randomized study of screening for ovarian cancer: a multicenter study in Japan | Q40190983 | ||
| Estimating the growth kinetics of experimental tumors from as few as two determinations of tumor size: implications for clinical oncology. | Q40423976 | ||
| Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. | Q45984954 | ||
| Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. | Q47950320 | ||
| Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. | Q50484612 | ||
| Ovarian volume related to age. | Q50660558 | ||
| Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. | Q50767903 | ||
| Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. | Q50801058 | ||
| Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? | Q51125402 | ||
| Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Q51129805 | ||
| Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. | Q51173327 | ||
| Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy. | Q51944838 | ||
| A mathematical model of breast and ovarian cancer treated with paclitaxel. | Q52252206 | ||
| Multi-type Galton-Watson process as a model for proliferating human tumour cell populations derived from stem cells: estimation of stem cell self-renewal probabilities in human ovarian carcinomas. | Q52646201 | ||
| The genesis and evolution of high-grade serous ovarian cancer | Q55053523 | ||
| Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging | Q56995376 | ||
| Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial | Q60628698 | ||
| Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered | Q61925516 | ||
| Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach | Q73153516 | ||
| Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q86063198 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | e0156661 | |
| P577 | publication date | 2016-06-03 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection | |
| P478 | volume | 11 |
Search more.